百时美施贵宝（BMY.N）及其合作伙伴赛科免疫周五表示，其实验性乳腺癌治疗药物在一项后期研究中，减缓了疾病进展，优于标准化疗。
Bristol Myers Squibb (BMY.N) and partner SystImmune said on Friday their experimental breast cancer treatment slowed disease progression compared to standard chemotherapy in a late-stage study.
该药物伊扎隆他单抗-布伦吉替康，将晚期激素受体阳性、HER2阴性乳腺癌患者的疾病恶化或死亡风险降低了59%，这些患者此前至少接受过一线化疗。
The drug, izalontamab brengitecan, reduced the risk of disease worsening or death by 59% in patients with advanced hormone-receptor-positive, HER2-negative breast cancer, who had failed at least one prior line of chemotherapy.
接受该药物治疗的患者平均8.2个月内癌症未增长，而接受标准化疗的患者为四个月。完整结果将在马德里举行的欧洲医学肿瘤学会大会上公布。
Patients treated with the drug lived for an average of 8.2 months without their cancer growing, compared to four months for those on standard chemotherapy. The full results will be presented at the European Society for Medical Oncology congress in Madrid.